Revolutionary Single-Shot Therapy Fights Alzheimer’s!
Alzheimer’s Treatment Briefing
Coverage period: March 3–March 9, 2026
Below are this week’s most meaningful, truly new developments, ranked by impact on treatment and access.[1][2]
Single-shot therapy turns brain support cells into plaque-eating machines
- Overview
Scientists at Washington University created a one-time injection that reprograms helpful brain cells called astrocytes to hunt and swallow sticky protein clumps (amyloid plaques) that harm the brain in Alzheimer's. In mice, early use kept brains completely clear of new plaques, while later use cut existing plaques in half within months.[1][2] (WashU Medicine, Neuroscience News) - Why this matters
Unlike monthly IV drugs that only slow plaque growth modestly, this durable, brain-wide cleanup could offer stronger protection with less hassle, paving the way for easier, more effective early treatment.
- Overview
Cancer drug blocks harmful brain over-connections in early Alzheimer's lab model
- Overview
A drug called eFT508, already used for cancer, stopped early brain wiring changes caused by protein bits in Alzheimer's. In rat brain cells, it fixed 70% of messed-up proteins and calmed overactive connections mimicking mild memory loss.[3] (EurekAlert) - Why this matters
Early brain over-wiring may spark memory problems; repurposing this safe drug could add a quick tool to protect thinking skills before full symptoms hit, speeding help without new approvals.
- Overview
Special brain cells normally flush out harmful tau proteins—fail in Alzheimer's
- Overview
Tanycytes, cells lining a brain fluid channel, normally suck harmful twisted proteins (tau) from brain fluid and dump them into blood. In Alzheimer's patients, these cells break down, letting tau build up, as shown in mice, cells, and human samples.[4] (Nature) - Why this matters
This reveals a natural cleanup system gone wrong, opening doors to drugs that boost these cells for better tau removal alongside plaque treatments, tackling another key brain damager.
- Overview
Mystery cell structures help tough brain cells fight tau damage
- Overview
Granulovacuolar bodies (GVBs)—odd packets inside neurons—mark super-resilient cells that ramp up protein factories to keep working despite tau attacks. In mice, these cells make key learning proteins normally, unlike damaged neighbors.[5] (Alzforum) - Why this matters
Spotting what makes some neurons survivors could inspire therapies to trigger the same defenses in others, buying time and boosting survival rates during tau spread.
- Overview
Low-dose lithium fails to help memory in mild thinking issues
- Overview
A two-year trial of adjustable low-dose lithium (average 195 mg/day) in 83 older adults with mild cognitive impairment showed no slowdown in memory or brain shrinkage compared to fake pills; only 25% had Alzheimer's proteins.[6] (Alzforum) - Why this matters
Past hype on lithium fizzles here, urging focus on proven paths like plaque/tau drugs; still, hints in protein-positive folks suggest refined versions (like lithium orotate) deserve checks.
- Overview
What this means for care right now
- Eye cell therapies
CAR-astrocyte tech eyes human tests—track trials for early plaque fighters as add-ons to shots like Leqembi.[2] - Test repurposed drugs
Discuss eFT508 or similar with docs for early stages; cancer safety profile means faster paths.[3] - Push clearance boosters
Blood tests for tau now guide care—future tanycyte/GVB drugs could pair for total protein purge.[4][5] - Skip unproven lithium
Stick to approved options; watch bigger trials but prioritize lifestyle + standards.[6]
Sources
- CARA therapy (March 5, 2026), WashU Medicine[1]
- CARA details (March 5, 2026), Neuroscience News, Science[2]
- Tanycytes tau clearance (March 5, 2026), Nature[4]
- eFT508 study (March 8, 2026), EurekAlert, Translational Psychiatry[3]
- GVBs resilience (March 6, 2026), Alzforum[5]
- Lithium trial (March 5, 2026), Alzforum[6]
If a week brings few blockbuster trial results, focus stays on building blocks for better care.